Applied Therapeutics, Inc. APLT
Set alert
0.10 USD 0.00 0.00%
At close · Jul 2
0.11 0.00 +2.04%
After hours · Jul 2, 4:00 PM ET
0.103 Day range 0.103
0.78 52-week range 10.62
- YTD
- +3.00%
- 1 year
- -81.62%
- Open
- 0.103
- Prev close
- 0.103
- Mkt cap
- 99.09M
- Vol
- 0
- Avg vol
- 5.16M
- EPS
- -1.42
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.103
- High
- 0.103
- Forward P/E
- -1.85
- Beta
- 2.02
- Short ratio
- 3.25
- Inst. own
- 103.35%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 7, 2024
- 50-d avg
- 6.47
- 200-d avg
- 5.81
- 1y target
- 5.92
2Y chart
Events in this range
- Mar 6, 2024Earnings: -0.33; estimate -0.15; surprise -120%
- May 9, 2024Earnings: -0.16; estimate -0.07; surprise -128.57%
- May 9, 2024Earnings: —; estimate -0.07; surprise —%
- Aug 7, 2024Earnings: -0.13; estimate -0.1; surprise -30%
- Aug 7, 2024Earnings: —; estimate -0.1; surprise —%
- Nov 7, 2024Earnings: -0.2; estimate -0.13; surprise -53.85%
- Nov 29, 2024Downgrade: RBC Capital · Outperform → Sector Perform
- Nov 29, 2024Rating: Baird · Outperform → Outperform
- Nov 29, 2024Rating: Citigroup · Buy → Buy
- Dec 2, 2024Downgrade: UBS · Buy → Neutral
- Dec 20, 2024Rating: RBC Capital · Sector Perform → Sector Perform
- Dec 23, 2024Downgrade: William Blair · Outperform → Market Perform
Signals (78)
| Name | Date | Ago |
|---|---|---|
| RSI: Oversold | Jan 26, 2026 | 9 months ago |
| RSI: Oversold | Dec 12, 2025 | 10 months ago |
| MACD: Buy Signal | Dec 4, 2025 | 11 months ago |
| SMA: Bearish | Nov 13, 2025 | 11 months ago |
| SMA: Bearish | Nov 13, 2025 | 11 months ago |
| RSI: Oversold | Nov 13, 2025 | 11 months ago |
| SMA: Bullish | Nov 11, 2025 | 11 months ago |
| SMA: Bearish | Nov 6, 2025 | 12 months ago |
| MACD: Sell Signal | Oct 28, 2025 | 1 year ago |
| RSI: Overbought | Oct 20, 2025 | 1 year ago |
| RSI: Overbought | Sep 26, 2025 | 1 year ago |
| SMA: Bullish | Sep 25, 2025 | 1 year ago |
| SMA: Bullish | Sep 25, 2025 | 1 year ago |
| MACD: Buy Signal | Sep 24, 2025 | 1 year ago |
| SMA: Bearish | Sep 23, 2025 | 1 year ago |
| SMA: Bullish | Sep 22, 2025 | 1 year ago |
| SMA: Bearish | Sep 8, 2025 | 1 year ago |
| MACD: Sell Signal | Sep 3, 2025 | 1 year ago |
| MACD: Buy Signal | Aug 18, 2025 | 1 year ago |
| MACD: Sell Signal | Jul 30, 2025 | 1 year ago |
| RSI: Overbought | Jul 23, 2025 | 1 year ago |
| SMA: Bullish | Jul 9, 2025 | 1 year ago |
| MACD: Buy Signal | Jul 7, 2025 | 1 year ago |
| MACD: Sell Signal | Jun 30, 2025 | 1 year ago |
| MACD: Buy Signal | Jun 26, 2025 | 1 year ago |
| MACD: Sell Signal | May 22, 2025 | 1 year ago |
| SMA: Bearish | May 20, 2025 | 1 year ago |
| RSI: Overbought | May 16, 2025 | 1 year ago |
| SMA: Bullish | May 14, 2025 | 1 year ago |
| SMA: Bearish | May 13, 2025 | 1 year ago |
| SMA: Bullish | May 12, 2025 | 1 year ago |
| SMA: Bearish | May 5, 2025 | 1 year ago |
| SMA: Bullish | May 2, 2025 | 1 year ago |
| MACD: Buy Signal | Apr 22, 2025 | 1 year ago |
| RSI: Oversold | Apr 8, 2025 | 1 year ago |
| MACD: Sell Signal | Apr 3, 2025 | 1 year ago |
| SMA: Bearish | Mar 24, 2025 | 1 year ago |
| SMA: Bullish | Mar 21, 2025 | 1 year ago |
| RSI: Oversold | Feb 27, 2025 | 1 year ago |
| RSI: Oversold | Feb 21, 2025 | 1 year ago |
| MACD: Buy Signal | Dec 20, 2024 | 1 year ago |
| SMA: Bearish | Nov 29, 2024 | 1 year ago |
| RSI: Oversold | Nov 29, 2024 | 1 year ago |
| SMA: Bearish | Nov 27, 2024 | 1 year ago |
| MACD: Sell Signal | Nov 27, 2024 | 1 year ago |
| MACD: Buy Signal | Nov 26, 2024 | 1 year ago |
| MACD: Sell Signal | Nov 13, 2024 | 1 year ago |
| RSI: Overbought | Nov 8, 2024 | 1 year ago |
| MACD: Buy Signal | Nov 6, 2024 | 1 year ago |
| MACD: Sell Signal | Oct 17, 2024 | 2 years ago |
| RSI: Overbought | Oct 15, 2024 | 2 years ago |
| MACD: Buy Signal | Oct 14, 2024 | 2 years ago |
| MACD: Sell Signal | Oct 7, 2024 | 2 years ago |
| RSI: Overbought | Sep 30, 2024 | 2 years ago |
| RSI: Overbought | Sep 24, 2024 | 2 years ago |
| SMA: Bullish | Sep 18, 2024 | 2 years ago |
| MACD: Buy Signal | Sep 18, 2024 | 2 years ago |
| RSI: Overbought | Sep 18, 2024 | 2 years ago |
| SMA: Bearish | Sep 10, 2024 | 2 years ago |
| MACD: Sell Signal | Aug 15, 2024 | 2 years ago |
| MACD: Buy Signal | Aug 1, 2024 | 2 years ago |
| MACD: Sell Signal | Jul 24, 2024 | 2 years ago |
| RSI: Overbought | Jul 15, 2024 | 2 years ago |
| MACD: Buy Signal | Jul 9, 2024 | 2 years ago |
| SMA: Bullish | Jul 5, 2024 | 2 years ago |
| SMA: Bearish | Jul 2, 2024 | 2 years ago |
| SMA: Bullish | Jun 27, 2024 | 2 years ago |
| SMA: Bearish | Jun 25, 2024 | 2 years ago |
| SMA: Bullish | Jun 24, 2024 | 2 years ago |
| MACD: Sell Signal | Jun 21, 2024 | 2 years ago |
| SMA: Bearish | Jun 18, 2024 | 2 years ago |
| SMA: Bullish | Jun 10, 2024 | 2 years ago |
| MACD: Buy Signal | May 28, 2024 | 2 years ago |
| MACD: Sell Signal | May 23, 2024 | 2 years ago |
| MACD: Buy Signal | May 3, 2024 | 2 years ago |
| RSI: Oversold | Apr 24, 2024 | 2 years ago |
| RSI: Oversold | Apr 19, 2024 | 2 years ago |
| RSI: Overbought | Mar 8, 2024 | 2 years ago |
Key statistics
- Market cap
- 99.09M
- Enterprise value
- 5.51M
- Trailing P/E
- 0.00
- Forward P/E
- -1.85
- PEG ratio
- 0.00
- Price / sales
- -467.40
- Price / book
- 16.70
- EPS (TTM)
- -1.42
- Beta
- 2.02
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- -212.00K
- Revenue growth
- 0.00%
- Free cash flow
- -3.58M
- Total cash
- 98.87M
- Total debt
- 1.97M
- Return on equity
- 0.00%
- Shares outstanding
- 116.36M
- Short % of float
- 13.60%
- 50-day average
- 6.47
- 200-day average
- 5.81
Analyst view
Consensus: buy
Buy
Price target (mean) 5.92 +5644.3% upside
Now 0.103
- Target (low)
- 1.50
- Target (mean)
- 5.92
- Target (high)
- 13.00
Ratings (0m) 6 3 buy · 3 hold · 0 sell
- Strong buy0
- Buy3
- Hold3
- Sell0
- Strong sell0
Next earnings
Aug 7, 2024
Expected Aug 7, 2024. Consensus EPS estimate -0.19413.
Financials — quick view
APLT Revenue — quarterly 1.00M
APLT Net income — quarterly -18.99M
APLT EPS — quarterly -0.13
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 7, 2024 | Sep 1, 2024 | -0.13 | -0.20 | -0.07 | -53.85% |
| Aug 7, 2024 | Jun 1, 2024 | -0.10 | -0.13 | -0.03 | -30.00% |
| Aug 7, 2024 | Jun 1, 2024 | -0.10 | — | — | — |
| May 9, 2024 | Mar 1, 2024 | -0.07 | -0.16 | -0.09 | -128.57% |
| May 9, 2024 | Mar 1, 2024 | -0.07 | — | — | — |
| Mar 6, 2024 | Dec 1, 2023 | -0.15 | -0.33 | -0.18 | -120.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 23, 2024 | William Blair | down | Outperform | Market Perform |
| Dec 20, 2024 | RBC Capital | main | Sector Perform | Sector Perform |
| Dec 2, 2024 | UBS | down | Buy | Neutral |
| Nov 29, 2024 | Citigroup | main | Buy | Buy |
| Nov 29, 2024 | Baird | main | Outperform | Outperform |
| Nov 29, 2024 | RBC Capital | down | Outperform | Sector Perform |
About Applied Therapeutics, Inc.
Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG. It also develops AT-001 (also called caficrestat) that is in phase 3 clinical trials to treat diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy; and AT-003, which is in preclinical studies for the treatment diabetic retinopathy. The company has exclusive license and supply agreement with Mercury Pharma Group Limited to commercialize drug products containing AT-007. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- appliedtherapeutics.com
News
- Head to Head Contrast: Q32 Bio (NASDAQ:QTTB) & Applied Therapeutics (NASDAQ:APLT)
- Immuron (NASDAQ:IMRN) and Applied Therapeutics (NASDAQ:APLT) Financial Analysis
- Analyzing Cartesian Therapeutics (NASDAQ:RNAC) and Applied Therapeutics (NASDAQ:APLT)
- Cycle Pharmaceuticals Completes Acquisition of Applied Therapeutics
- Cycle Pharmaceuticals Announces Extension of Applied Therapeutics Tender Offer
- Applied Therapeutics Shares Letter to Stockholders Recommending Tender of Shares Following Offer Expiration Extension
- Cycle Pharmaceuticals Announces Extension of Applied Therapeutics Tender Offer
- Cycle Pharmaceuticals Announces Extension of Applied Therapeutics Tender Offer
- Why RF Industries Shares Are Trading Higher By 21%; Here Are 20 Stocks Moving Premarket
- Applied Therapeutics Inc. (NASDAQ:APLT) Short Interest Update
Your note
Sign in to keep a note on APLT — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ALEXANDRIA REAL ESTATE EQUITIES INC | Beneficial Owner of more than 10% of a Class of Security | Sale | Jun 4, 2024 | 0 |
| FUNTLEYDER LESLIE D | Chief Executive Officer | Stock Award(Grant) | Dec 18, 2024 | 427,911 |
| HOOKS CORWIN DALE | Officer | Stock Award(Grant) | Apr 11, 2024 | 300,000 |
| JOHNSON JOHN H. | Officer and Director | Stock Award(Grant) | Dec 18, 2024 | 500,000 |
| KANTER STACY J | Director | Stock Award(Grant) | Jun 5, 2024 | 108,000 |
| LERNER TEENA L. PH.D. | Director | Stock Award(Grant) | Jun 5, 2024 | 105,422 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Janus Henderson Group PLC | 9.06% | 10,541,528 | 8.98M | Sep 29, 2024 |
| Morgan Stanley | 8.51% | 9,904,530 | 8.43M | Sep 29, 2024 |
| VR Adviser, LLC | 8.44% | 9,825,000 | 8.37M | Sep 29, 2024 |
| Perceptive Advisors Llc | 6.88% | 8,005,000 | 6.82M | Sep 29, 2024 |
| Blackrock Inc. | 5.97% | 6,942,699 | 5.91M | Sep 29, 2024 |
| Franklin Resources, Inc. | 5.84% | 6,800,910 | 5.79M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Franklin Strategic Series-Franklin Biotechnology Discove | 2.97% | 3,450,500 | 2.94M | Jul 30, 2024 |
| Vanguard Total Stock Market Index Fund | 2.71% | 3,153,938 | 2.69M | Sep 29, 2024 |
| Simplify Exchange Traded Fds-Simplify Propel Opportunities ETF | 2.42% | 2,817,505 | 2.40M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 2.14% | 2,486,153 | 2.12M | Oct 30, 2024 |
| SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF | 1.57% | 1,830,616 | 1.56M | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 0.99% | 1,151,026 | 980.21K | Sep 29, 2024 |